EUCTR2008-006181-28-BE进行中（未招募）不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 18 years old
- •Patients with histological diagnosis of metastatic papillary renal cell carcinoma, type I or II, centrally confirmed (relevant slides (and blocks if available) must be sent for central reading within one month from enrollment: if this is not feasible the patient cannot be considered eligible)
- •Patients with at least one measurable lesion at baseline as per RECIST criteria
- •Patients with an ECOG performance status of = 1
- •Adequate bone marrow function as shown by: ANC = 1.5 x 109/L, Platelets = 100 x 109/L, Hb >9 g/dL.
- •Adequate liver function as shown by: serum bilirubin: = 1.5 x ULN, INR< 1.3 (or <3 on anticoagulants), ALT and AST = 2.5x ULN. For patients with known liver metastases: AST and ALT = 5x ULN.
- •Adequate renal function as shown by: serum creatinine = 2.0 x ULN.
- •Life expectancy = 3 months
- •Fasting serum cholesterol =300 mg/dL or =7.5 mmol/L and fasting triglycerides = 2.5 x ULN. NOTE: in case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
- •Women of childbearing potential must have had a negative urine or blood pregnancy test within one week prior to the administration of the study treatment start.
- •Patients who give a written informed consent obtained according to local guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who had radiation therapy within 28 days prior to start of study treatment (palliative radiotherapy to bone lesions allowed within 2 weeks prior to study treatment start).
- •Patients who have received any prior systemic treatment for their metastatic RCC, such as sunitinib, sorafenib, and bevacizumab.
- •Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus, everolimus).
- •Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients.
- •Patients with uncontrolled central nervous system (CNS) metastases.
- •Patients receiving chronic systemic treatment with corticosteroids (dose of = 10 mg/day methylprednisone equivalent) or another immunosuppressive agent. Inhaled and topical steroids are acceptable, as well as opotherapy after bilateral adrenal gland removal.
- •Patients with a known history of HIV seropositivity.
- •Patients with autoimmune hepatitis.
- •Patients with an active, bleeding diathesis.
- •Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
- •Patients who have a history of another primary malignancy and off treatment for = 3 years, with the exception of non-melanoma skin cancer and carcinoma in situ of the uterine cervix.
- •Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not acceptable.
- •Patients who are using other investigational agents or who had received investigational drugs = 4 weeks prior to study treatment start.
- •Patients unwilling or unable to comply with the protocol.
- •Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A (Rifabutin, Rifampicin, Clarithromycin, Ketoconazole, Itroconazole, Voriconazole, Ritinavir, Telithromycin) within the last 5 days prior to randomization
研究者
相似试验
进行中（未招募）
不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer - RAPTORPatients who have metastatic papillary cancer of the kidney and have not received prior systemic treatment for their metastatic RCC. This multicenter international trial will enroll a maximum of 60 patients over a period of approximately 12 months.MedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-006181-28-FRovartis Pharma Services AG60
进行中（未招募）
不适用
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer - RAPTOREUCTR2008-006181-28-DEovartis Pharma Services AG55
进行中（未招募）
1 期
A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancerEUCTR2008-006181-28-GBovartis Pharma Services AG92
进行中（未招募）
1 期
A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyPalliative patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyEUCTR2008-004575-21-BECliniques Universitaires St Luc40
进行中（未招募）
1 期
A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapyEUCTR2008-004575-21-FRCliniques Universitaires St Luc40